• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations

    3/25/25 6:00:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email

    In this first-of-its-kind partnership for its Dental Solutions business, Solventum, formerly 3M Health Care, is striving to focus on longevity and durability of permanent same-day restorative dental offerings, reaffirming its commitment to solving industry's toughest problems

    Partnership aims to integrate innovative new material science and disruptive technology like chairside 3D printing to optimize workflows, enhance procedural efficiency and benefit both patients and practitioners

    ST. PAUL, Minn., March 25, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV), the leader in dental composites and restorative dentistry, today announced a strategic partnership with SprintRay, a leading provider of chairside 3D dental printing, to meet the needs of dentists with in-office chairside 3D printed crowns, inlays, onlays and more. This research and development (R&D) and commercialization agreement is focused on developing and bringing to market high-quality, durable and permanent same-day restorations – with the quality patients and dentists expect from the current multi-visit laboratory fabricated procedures.

    Solventum: Group portrait of a team of three dental professionals on a dark green background.

    Solventum Dental Solutions connects leading-edge materials with data science to help dentists solve their toughest challenges with products such as Filtek™ Easy Match Universal Restorative, Filtek™ Matrix, Scotchbond™ Universal and RelyX™ Universal Cement. SprintRay offers innovative chairside end-to-end 3D printing ecosystems, which create a platform for a wide range of restorative dental applications.

    With Solventum's legacy of best-in-class material science with leading restorative materials, and SprintRay's innovative technology, the partnership aims to bring to market the first permanent chairside, 3D printed crown. Together, Solventum and SprintRay anticipate improvement in patient experience and outcomes through fewer office visits – driving practice efficiency, and ultimately, delivering the outcomes patients and providers demand.

    "Imagine a world where your dentist can create a crown that can last decades in a matter of minutes," said Karim Mansour, President, Dental Solutions, Solventum. "We believe this partnership will revolutionize the way dentists and orthodontists care for patients with in-office production, offering a simplified procedure that we anticipate will improve outcomes and experiences, reduce chair time and lower treatment costs. This collaboration allows us to integrate the latest technological advancements into our proven restorative solutions, ensuring we remain at the forefront of dental innovation to deliver unparalleled care to our patients."

    Offering cutting-edge 3D printing technology directly to dentists and orthodontists will streamline care for patients and providers, allowing the delivery of same-visit dentistry and introducing a market for permanent 3D printed crowns, inlays, onlays and more. 

    "Together, we can make a significant impact in restorative dentistry by building exceptional products for same-visit treatment," said SprintRay CEO Amir Mansouri. "Our partnership with Solventum is a key collaboration and commitment to making a difference in people's oral health as well as enabling high-quality and cost-effective dental restorations across the globe."

    The announcement of the partnership aligns with Solventum's legacy of quality material science and is one example of biasing resources towards growth while strengthening digital capabilities, two elements of Solventum's previously announced three-phased plan. As the winner of seven Dental Advisor awards in 2024, the partnership follows four new product introductions launched in 2024, including:

    • 3M™ Clarity™ Precision Grip Attachments, the first 3D printed aligner attachments
    • 3M™ Clinpro™ Clear Fluoride Treatment, a new water-based formula for smoother application and a more comfortable patient experience
    • Clarity™ Flex + Force Aligners, new proprietary multi-layer copolymer extruded in different thicknesses to best express varying degrees of movement
    • 3M™ Filtek™ Easy Match Universal Restorative features naturally adaptive opacity and offers an intuitive shade selection process to simplify direct restorative procedures

    Solventum will share more details about the strategic partnership at the International Dental Show (IDS) 2025 on March 26 in Cologne, Germany.

    About Solventum

    At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

    Forward-Looking Statements

    This news release contains forward-looking information about Solventum's financial results, estimates, and business prospects that involve substantial risks and uncertainties. In particular, statements regarding the future performance of Solventum, including guidance for 2024, are forward-looking statements. You can identify these statements by the use of words such as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control; (2) operational execution risks; (3) damage to our reputation or our brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events; (5) ; the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (6) reduction in customers' research budgets or government funding; (7) the timing and market acceptance of Solventum's new product and service offerings; (8) ongoing working relationships with certain key healthcare professionals; (9) changes in reimbursement practices of governments or private payers or other cost containment measures; (10) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (11) risks related to the highly regulated environment in which Solventum operates; (12) Solventum's failure to obtain, maintain, protect, or effectively enforce its intellectual property ("IP") rights.

    Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

    Solventum Logo (PRNewsfoto/3M Healthcare US Opco  LLC)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-partners-with-sprintray-to-disrupt-the-digital-dentistry-market-with-high-quality-permanent-same-day-restorations-302411305.html

    SOURCE Solventum

    Get the next $SOLV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    1/26/2026$97.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/20/2026$100.00Neutral → Outperform
    Mizuho
    12/2/2025$100.00Neutral → Buy
    BTIG Research
    10/1/2025$77.00Neutral
    UBS
    9/11/2025$80.00Hold
    Jefferies
    7/15/2025$103.00Equal-Weight → Overweight
    Morgan Stanley
    7/1/2025$90.00Hold → Buy
    Argus
    6/6/2025Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Solventum upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Solventum from Sector Weight to Overweight and set a new price target of $97.00

    1/26/26 8:32:07 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum upgraded by Mizuho with a new price target

    Mizuho upgraded Solventum from Neutral to Outperform and set a new price target of $100.00

    1/20/26 8:47:32 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum upgraded by BTIG Research with a new price target

    BTIG Research upgraded Solventum from Neutral to Buy and set a new price target of $100.00

    12/2/25 8:17:55 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Information Officer Landucci Amy covered exercise/tax liability with 10,453 shares and converted options into 26,921 shares, increasing direct ownership by 87% to 35,419 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    2/3/26 10:01:46 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Chief Human Resources Officer Gomez Tammy L converted options into 4,342 shares and covered exercise/tax liability with 1,332 shares, increasing direct ownership by 53% to 8,665 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    1/5/26 5:34:29 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Solventum Corporation

    4 - Solventum Corp (0001964738) (Issuer)

    12/3/25 7:22:15 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance

    Reported sales decreased 3.7%; organic sales increased 3.5%Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 26, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 HighlightsSales of $2 billion decreased 3.7% on a reported basis; an increase of 3.5% on an organic basisGAAP diluted earnings per share of $0.36; adjusted diluted earnings per share of $1.57Operating cash flow of $96 million; free cash flow of $33 million"So

    2/26/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026

    ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2026 outlook. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Feb. 26, 2026 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 Internation

    2/3/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Completes Acquisition of Acera Surgical

    Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S.Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacencyST. PAUL, Minn., Dec. 23, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care. "Announcing and completing our first strategic ac

    12/23/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    SEC Filings

    View All

    SEC Form 10-K filed by Solventum Corporation

    10-K - Solventum Corp (0001964738) (Filer)

    2/27/26 1:40:50 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Solventum Corp (0001964738) (Filer)

    2/26/26 4:08:05 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Solventum Corporation

    SCHEDULE 13G/A - Solventum Corp (0001964738) (Subject)

    1/27/26 12:15:19 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Financials

    Live finance-specific insights

    View All

    Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance

    Reported sales decreased 3.7%; organic sales increased 3.5%Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 26, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 HighlightsSales of $2 billion decreased 3.7% on a reported basis; an increase of 3.5% on an organic basisGAAP diluted earnings per share of $0.36; adjusted diluted earnings per share of $1.57Operating cash flow of $96 million; free cash flow of $33 million"So

    2/26/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026

    ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2026 outlook. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Feb. 26, 2026 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 Internation

    2/3/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Completes Acquisition of Acera Surgical

    Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S.Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacencyST. PAUL, Minn., Dec. 23, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care. "Announcing and completing our first strategic ac

    12/23/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    View All

    Solventum Appoints Heather Knight as Chief Commercial Officer

    ST. PAUL, Minn., Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sale

    10/21/25 5:00:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

    BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

    2/11/25 8:00:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

    Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

    1/8/25 6:30:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/12/24 5:47:11 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/4/24 1:47:43 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care